I Hate Dialysis Message Board
Dialysis Discussion => Dialysis: News Articles => Topic started by: Marlon on May 18, 2008, 07:23:46 PM
-
I know we are all different and new studies will be done next year, with results the following year. While I get good support and learn much here, I have noticed that very knowledgable people pass away while on dialysis.If my cardio vascular system which they say is a leading cause of death, is very well treated will increasing the days of dialysis improve life span or is a transplant needed, I wonder.
http://kidney.niddk.nih.gov/about/Research_Updates/KidneyDiseaseSpr07/1.htm
With 10 large kidney studies scheduled to end between fiscal year 2007 and 2009, the NIDDK is seeking the most promising, compelling, and feasible opportunities that address what research is needed to reduce the morbidity and mortality of kidney disease.
The key challenge in treating ESRD is that mortality remains stubbornly high, especially in the first year of hemodialysis. Studies have failed to show that increased dialysis dose improves outcomes. While fistula use in dialysis is associated with lower morbidity, mortality, and cost, 25 to 50 percent of fistulas fail to mature, increasing the risk of sepsis from temporary catheters.
The ESRD group proposed
determining if the mortality and cardiovascular event rate could be reduced by beta blockers and renin angiotensin system blockers
conducting an observational study to identify determinants of fistula maturation
assessing the need for the invasive pretransplant evaluation of CVD in transplant candidates with a randomized, controlled study
conducting an observational study to determine the causes of the high mortality and morbidity in the first 90 days of dialysis
developing optimal techniques to reduce the calcium-phosphorus product by dialysis and optimize use of vitamin D to reduce vascular calcification and CVD
studying pediatric ESRD patients with a focus on adherence and neurocognitive function
The NIDDK will review, clarify, and further develop these concepts for potential incorporation into the Institute’s research agenda. For information about NIDDK clinical trials for kidney disease, visit www.kidney.niddk.nih.gov/clinicaltrials.
The large kidney studies scheduled to end between fiscal year 2007 and 2009 are the
African American Study of Kidney Disease and Hypertension (AASK)
Family Investigation of Nephropathy of Diabetes (FIND)
Acute Renal Failure Trial Network (ATN) Dialysis Study
Dialysis Access Clinical Trials Consortium (DAC)
Frequent Hemodialysis Network (FHN)
Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT)
Focal Segmental Glomerulosclerosis (FSGS)
Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)
Chronic Kidney Disease in Children Prospective Cohort Study (CKid)
Chronic Renal Insufficiency Cohort (CRIC)